Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling-Reference-Cited by-同舟云学术

Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling

Published:2022-09 Issue: Volume:153 Page:113509
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Wu Chunnuan,Liu Huining,Yu Shuang,Ren Congcong,Zhang Jie,Wang Guopeng,Li Bole,Liu Yang

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference36 articles.

1. Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: an open-label, phase 3 exploratory study;Inagaki;J. Diabetes Investig.,2018

2. A thorough QTc study confirms early pharmacokinetics/QTc modeling: a supratherapeutic dose of omarigliptin, a once-weekly DPP-4 inhibitor, does not prolong the QTc interval;Tatosian;Clin. Pharmacol. Drug Dev.,2016

3. Trelagliptin: first global approval;McKeage;Drugs,2015

4. Omarigliptin: first global approval;Burness;Drugs,2015

5. Pharmaceuticals and Medical Devices Agency Available from 〈https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400256_3969024F1028_1_15〉.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Physiologically Based Pharmacokinetic Model for Predicting Vildagliptin Pharmacokinetics: Insights into Dosing in Renal Impairment;Pharmaceuticals;2024-07-10

2. Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models;Expert Opinion on Drug Metabolism & Toxicology;2024-01-31

3. Regulatory Requirements and Applications of Physiologically Based Pharmacokinetic Models;ADME Processes in Pharmaceutical Sciences;2024

4. Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling;ACS OMEGA;2023

5. Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling;ACS Omega;2023-04-03